Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593149 · ClinicalTrials.gov registry record · NA
Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
A NA study, sponsored by Pursuit Vascular.
- Completed
- Registry status
- NA
- Development phase
- 1,902
- Enrollment target
NCT02593149: Completed NA study, sponsored by Pursuit Vascular.
NCT02593149 is a NA study that has completed, run by Pursuit Vascular. The registered enrollment target is 1,902 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02593149, a NA study, has completed, sponsored by Pursuit Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,902 participants
- Enrollment target
Study Summary
To assess blood stream infections in participants using two FDA-cleared devices: ClearGuard HD end caps compared to the Tego® connector with the CurosTM for Tego disinfecting port protector.
Primary Outcome
This was calculated by dividing the cumulative number of PBCs by cumulative time at-risk as follows. The National Healthcare Safety Network (NHSN) Center for Disease Control (CDC) 21-day outpatient hemodialysis patient rule is as follows: A PBC is considered a new event and counted only if it occurred 21 days or more after a previously reported PBC in the same patient; new PBC events are based on blood cultures drawn as an outpatient or within one calendar day after a hospital admission. Follow
Interventions
- DEVICE ClearGuard HD End Cap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,902 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-11 |
| Phase | NA |
What the finished NCT02593149 record still lists
NCT02593149 is an interventional study that assigns participants to a tested intervention. Its 1,902 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 1 intervention - of which ClearGuard HD End Cap is the first listed.
NCT02593149 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02593149 about?
NCT02593149 is a clinical study titled "Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap". To assess blood stream infections in participants using two FDA-cleared devices: ClearGuard HD end caps compared to the Tego® connector with the CurosTM for Tego disinfecting port protector.
What is the current status of trial NCT02593149?
This trial is currently completed. It is a NA study. The enrollment target is 1,902 participants. The study started on 2015-11. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02593149?
The interventions under investigation include: ClearGuard HD End Cap (DEVICE).
Who is sponsoring clinical trial NCT02593149?
This trial is sponsored by Pursuit Vascular, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02593149's enrollment target sits among peer trials
1,902 55th of 2000 higher than 1,946 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
- NCT07228234 · 1,900 participants · NA
Evaluating Mammography Communication Approaches
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia